Eli Lilly (LLY) and Camurus entered into a collaboration and license agreement granting Lilly exclusive global rights to develop, manufacture, and commercialize incretin-based therapies using Camurus' FluidCrystal technology for cardiometabolic conditions.
The deal covers up to four of Lilly's proprietary drug compounds, Camurus said in a Tuesday statement.
Under the terms, Camurus is eligible to receive up to $290 million in upfront, development, and regulatory milestone payments, plus up to $580 million in sales-based milestones and tiered mid-single-digit royalties on global net sales.
Shares of Eli Lilly were up nearly 1% in recent trading.
Price: 754.22, Change: +7.04, Percent Change: +0.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.